NCT01668004View on ClinicalTrials.gov

The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

September 3, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Ankylosing Spondylitis
Interventions
BIOLOGICAL

Golimumab

GLM 50 mg subcutaneously once monthly.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) | Biotech Hunter | Biotech Hunter